See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic, used to treat various bacterial infections, including skin infections, intra-abdominal infections, and community-acquired pneumonia [1]. It functions by inhibiting protein synthesis in bacteria, thereby preventing their growth and replication [1]. However, the question at hand is how tigecycline affects patients.

Tigecycline has been associated with several adverse effects in patients. According to the FDA, the most common side effects include nausea and vomiting, which occur in more than 25% of patients [2]. Additionally, diarrhea, dizziness, and headache are also common, affecting 1-10% of patients [2].

More serious side effects, although less common, have also been reported. These include severe diarrhea caused by Clostridium difficile, which can lead to colitis and other intestinal problems [2]. Furthermore, tigecycline has been linked to an increased risk of death compared to other antibiotics, particularly in patients with severe infections [3]. This risk is still being investigated, and the FDA has issued a warning regarding its use in critically ill patients [3].

It is important to note that tigecycline, like all antibiotics, can contribute to antibiotic resistance [1]. Misuse or overuse of tigecycline can lead to bacteria developing resistance to its effects, making it less effective in treating infections [1].

In summary, tigecycline affects patients by treating bacterial infections but can also cause various adverse effects, such as nausea, vomiting, and diarrhea. More severe side effects, including an increased risk of death in critically ill patients, have also been reported [2][3]. Additionally, tigecycline can contribute to antibiotic resistance [1].

Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/drugs/tigecycline
[2] U.S. Food and Drug Administration. (2017, August). Tygacil (tigecycline) for injection, for intravenous use. Retrieved from https://www.fda.gov/media/73341/download
[3] U.S. Food and Drug Administration. (2013, March). FDA drug safety communication: FDA review finds increased risk of death with tigecycline (Tygacil) compared to other antibiotics. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-increased-risk-death-tigecycline-tygacil-compared